Development of Molecular Predictors to Treatment in Men with Metastatic Castration-Resistant Prostate Cancer

Full Title

Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC)


The benefits of hormone treatments for men with prostate cancer that has metastasized (spread to other organs) do not last. Over time, many prostate cancers continue to grow despite hormonal therapies (and are called “castration-resistant” prostate cancer, or CRPC).

Potent anti-androgen drugs, such as enzalutamide or abiraterone, and chemotherapy with docetaxel or cabazitaxel are current options for metastatic CRPC. However, doctors try to use them all without knowing who is most likely to respond. In this study, physicians want to see if they can predict which treatment a man will best respond to by using blood-based biomarkers.

Patients will begin treatment with either enzalutamide or abiraterone acetate. If the cancer continues to grow, they may be offered docetaxel or cabazitaxel. Enzalutamide and abiraterone are taken orally (by mouth), while docetaxel and cabazitaxel are given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Men must have metastatic CRPC and be considered for treatment with enzalutamide or abiraterone.

For more information about this study and to inquire about eligibility, please contact Dr. Daniel Danila at 646-422-4612.